Adverse outcome pathway development II: best practices.
Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, Landesmann B, Lettieri T, Munn S, Nepelska M, Ottinger MA, Vergauwen L, Whelan M.
Villeneuve DL, et al. Among authors: crump d.
Toxicol Sci. 2014 Dec;142(2):321-30. doi: 10.1093/toxsci/kfu200.
Toxicol Sci. 2014.
PMID: 25466379
Free PMC article.